| Autor: |
Diaz Quiroz JF; Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York 12180, United States., Rodriguez PD; Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York 12180, United States., Erndt-Marino JD; Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York 12180, United States., Guiza V; Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York 12180, United States., Balouch B; Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York 12180, United States., Graf T; Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York 12180, United States., Reichert WM; Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708, United States., Russell B; Institute of Biosciences and Technology, Texas A&M Health Science Center, College Station, Texas 77843, United States., Höök M; Institute of Biosciences and Technology, Texas A&M Health Science Center, College Station, Texas 77843, United States., Hahn MS; Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York 12180, United States. |
| Abstrakt: |
Achieving graft endothelialization following implantation continues to be a challenge in the development of "off-the-shelf," small-caliber, arterial prostheses. Coating grafts with biomolecules to support the retention, migration, and differentiation of adherent endothelial precursor cells (EPCs) is a promising approach toward improving graft endothelialization. D esigner C ollagen Scl2- 2 with 1 integrin binding site per strand (DC2-1X) is a Streptococcus pyogenes -derived, collagen-like protein that has previously been evaluated as a graft coating due to its ability to resist platelet aggregation and to promote attachment and migration of "late outgrowth" EPCs (EOCs). However, these prior assessments were performed in the absence of physiological shear. In addition, although DC2-1X coatings supported increased migration rates relative to native collagen coatings, EOC attachment and spreading remained inferior to collagen controls at all DC2-1X concentrations assayed. Thus, the objectives of the present work were the following: (1) to improve EOC attachment on DC2 coatings by modulating the number and spacing of DC2 integrin binding sites (IBS) and (2) to evaluate the retention, migration, and differentiation of adherent EOCs under physiological shear stress. Using single point mutations, three novel DC2 variants were generated containing either two IBS (DC2-2X) or three IBS (DC2-3X1 and DC2-3X2) per strand. After initial evaluation of the potential of each DC2 variant to support increased EOC attachment relative to DC2-1X, DC2-2X and DC2-3X1 coatings were further assessed under physiological shear for their capacity to promote EOC retention, migration, and differentiation relative to DC2-1X and collagen controls. An increase in the number of IBS from 1 to 3 significantly improved EOC retention on DC2 coatings while also supporting increased average migration rates. Moreover, EOCs on DC2-3X1 coatings showed increased gene-level expression of intermediate endothelial cell differentiation markers relative to collagen. Overall, the current results suggest that DC2-3X1 warrants further investigation as a vascular graft coating. |
